Polymorphisms of oxidation at carbon centers of drugs and their clinical significance.
about
Isolation and sequence of a human cytochrome P-450 cDNA cloneTesting for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism--histograms and probit plots.The use of single-nucleotide polymorphism maps in pharmacogenomics.Polymorphism in the metabolism of drugs, including antidepressant drugs: comments on phenotypingEnantiospecific analysis by capillary electrophoresis: applications in drug metabolism and pharmacokinetics.Roles of cytochrome p450 in development.Differential foetal development of the O- and N-demethylation of codeine and dextromethorphan in manDiscovery of altered pharmacokinetics of CGP 15 210 G in poor hydroxylators of debrisoquine during early drug development.Antipyrine clearance and metabolite formation in children with congenital adrenal hyperplasia.Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine.Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1.Desipramine pharmacokinetics in Chinese and Caucasian volunteers.Polymorphism of theophylline metabolism in man.Comparative biology of test species.Clinical pharmacology. Possible clinical importance of genetic differences in drug metabolismThe human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene.The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934----A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3' splice recognition siteThe gene CYP3 encoding P450pcn1 (nifedipine oxidase) is tightly linked to the gene COL1A2 encoding collagen type 1 alpha on 7q21-q22.1.Single-dose pharmacokinetics of ceftriaxone in healthy Chinese adults.Genetic heterogeneity of histamine H2-receptors in the mouse vas deferens.Drug metabolism and pharmacogenetics: the British contribution to fields of international significanceCharacterization of a human liver cytochrome P-450 involved in the oxidation of debrisoquine and other drugs by using antibodies raised to the analogous rat enzyme.A review of the clinical pharmacokinetics and metabolism of the alpha 1-adrenoceptor antagonist indoramin.Approaches to deorphanization of human and microbial cytochrome P450 enzymes.Comparative aspects of the mammalian cytochrome P450 IV gene family.Genetic factors in toxicology: implications for toxicological screening.Basic concepts in drug metabolism: Part I.Pharmacokinetic implications of lorcainide therapy in patients with normal and depressed cardiac function.Enzymatic activation of chemicals to toxic metabolites.Dose-dependent pharmacokinetics: emphasis on phase I metabolism.Advances in genetics and immunology: the importance of basic research to prevention of occupational diseases.A history of drug metabolism in the United Kingdom.Cytochrome P450 monooxygenases and interactions of psychotropic drugs: a five-year update.Phenotypic debrisoquine 4-hydroxylase activity among extensive metabolizers is unrelated to genotype as determined by the Xba-I restriction fragment length polymorphism.Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist?The Polymorphic Metabolism of Dextromethorphan
P2860
Q24568198-F9FE9D2D-69C5-4FC9-B504-F8FAABBA7C1BQ30976699-A6C210D7-8999-4A3E-B828-9A6F3E001DB6Q33913441-9593F53D-624F-47B0-9CED-944C4CA8CBB1Q33921325-E5C8B461-8986-4ECA-8F17-1327D4F559BFQ33958062-58FD3D0B-204F-4CDE-9645-467947E41F5BQ34346319-8C8BC4B9-FE2E-4CEF-B498-94FC930BF257Q34358650-B8C376A5-5D93-46DD-B131-24405E629E5EQ34446502-0E7588BE-9374-46D3-B7A3-0B65286C29A2Q34447041-B27686EA-A0E7-4C38-A59E-D490D0CA46D1Q34512351-13145E80-BA34-4831-A6DA-80784566A860Q34569386-114B210B-811E-47A1-BC5C-40747B5101F7Q34621200-440A2D4E-82F7-43CE-A2A1-F0995D87DD50Q34626564-8CE45232-608A-4FDD-8DB0-BEA1ADE099F7Q34660522-419DCFD0-1EF4-4D82-8446-AFC0E3F62202Q34785779-4D9740F6-7C02-4BF6-A705-9FDB5B778427Q35197475-6FC6A79A-89F7-48EB-BC5E-3F9D2EB856E3Q35198610-78BFD4A9-B84E-42F9-A757-9E48C96EC3B6Q35246919-AD44E635-4039-43E2-989D-F2472D8A8507Q35569544-BB37BBFE-3411-4621-B253-CA52E746FC40Q36004019-1AE93706-81E8-485C-879B-FBD2F2F1ED6BQ36364455-7783A517-4204-4715-AE1A-EA3BE5791AACQ37578460-B011B9A4-BFB4-4D1F-AD0C-6F383B174E13Q37611552-BE8B66E7-B76C-47E3-B4BB-20E0ED625F9AQ37759731-29D1BF02-359A-4BB5-9D2D-6369093EF8E6Q38719077-58F84B51-043C-4311-9520-859AD51C30C5Q39673571-DF9E3E96-6369-43B0-9BDE-7135C7D73FB9Q39679807-C59CC8B3-AC2C-4BC1-8C34-C12620740E2BQ39786032-7B417C0B-9384-492E-82E2-FA44476A4D22Q39847955-54555D5A-56C1-45BF-896D-69D432E9DC41Q40153504-D3030FCE-7490-4765-BE57-5AAD8FA961BCQ40183908-7C3071C5-517E-4DA0-88C4-7758ABEE572AQ40885948-713A617F-E38D-4AF5-8EB9-9775CE59377EQ40949311-287A3E3C-081B-4D53-87EC-747137777F41Q41135854-4DFD193C-FC79-483D-ADB2-9C04ACAA0486Q43109060-3A8A83AA-756A-4838-9D9E-BEEC2EE0795EQ57380871-1DFA15BD-0269-4221-BC59-8E85DE16896F
P2860
Polymorphisms of oxidation at carbon centers of drugs and their clinical significance.
description
1979 nî lūn-bûn
@nan
1979年の論文
@ja
1979年論文
@yue
1979年論文
@zh-hant
1979年論文
@zh-hk
1979年論文
@zh-mo
1979年論文
@zh-tw
1979年论文
@wuu
1979年论文
@zh
1979年论文
@zh-cn
name
Polymorphisms of oxidation at carbon centers of drugs and their clinical significance.
@ast
Polymorphisms of oxidation at carbon centers of drugs and their clinical significance.
@en
type
label
Polymorphisms of oxidation at carbon centers of drugs and their clinical significance.
@ast
Polymorphisms of oxidation at carbon centers of drugs and their clinical significance.
@en
prefLabel
Polymorphisms of oxidation at carbon centers of drugs and their clinical significance.
@ast
Polymorphisms of oxidation at carbon centers of drugs and their clinical significance.
@en
P2860
P1476
Polymorphisms of oxidation at carbon centers of drugs and their clinical significance.
@en
P2093
P2860
P304
P356
10.3109/03602537908993896
P407
P577
1979-01-01T00:00:00Z